Trust Co. of Vermont bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 116 shares of the pharmaceutical company's stock, valued at approximately $33,000.
A number of other hedge funds have also modified their holdings of the business. Procyon Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 2.8% during the 2nd quarter. Procyon Advisors LLC now owns 1,366 shares of the pharmaceutical company's stock worth $385,000 after purchasing an additional 37 shares in the last quarter. Nkcfo LLC increased its stake in shares of Vertex Pharmaceuticals by 0.5% during the 2nd quarter. Nkcfo LLC now owns 8,515 shares of the pharmaceutical company's stock worth $2,399,000 after purchasing an additional 40 shares in the last quarter. J2 Capital Management Inc grew its stake in Vertex Pharmaceuticals by 2.2% in the 1st quarter. J2 Capital Management Inc now owns 1,915 shares of the pharmaceutical company's stock worth $500,000 after acquiring an additional 41 shares during the period. CHURCHILL MANAGEMENT Corp grew its stake in Vertex Pharmaceuticals by 0.5% in the 2nd quarter. CHURCHILL MANAGEMENT Corp now owns 7,935 shares of the pharmaceutical company's stock worth $2,236,000 after acquiring an additional 42 shares during the period. Finally, Evoke Wealth LLC grew its stake in Vertex Pharmaceuticals by 32.8% in the 1st quarter. Evoke Wealth LLC now owns 174 shares of the pharmaceutical company's stock worth $45,000 after acquiring an additional 43 shares during the period. 91.33% of the stock is owned by hedge funds and other institutional investors.
其他一些对冲基金也调整了对该公司的持股比例。Procyon Advisors LLC在第二季度将其在Vertex制药公司的股份增加了2.8%。Procyon Advisors LLC现在拥有这家制药公司1,366股股票，价值385,000美元，上个季度又购买了37股。Nkcfo LLC在第二季度将其在Vertex PharmPharmticals的股份增加了0.5%。Nkcfo LLC现在拥有这家制药公司8,515股股票，价值2,399,000美元，上个季度又购买了40股。第一季度，J2资本管理公司在Vertex PharmPharmticals的持股增加了2.2%。J2资本管理公司在此期间额外收购了41股，现在拥有1,915股这家制药公司的股票，价值50万美元。丘吉尔管理公司在第二季度增持了Vertex PharmPharmticals 0.5%的股份。丘吉尔管理公司(Churchill Management Corp)在此期间额外收购了42股，目前拥有7,935股辉瑞股票，价值2,236,000美元。最后，Evoke Wealth LLC在第一季度增持了Vertex PharmPharmticals 32.8%的股份。Evoke Wealth LLC在此期间额外收购了43股，现在拥有174股这家制药公司的股票，价值4.5万美元。91.33%的股票由对冲基金和其他机构投资者持有。
Wall Street Analyst Weigh In
Several analysts have commented on the stock. Argus lifted their target price on shares of Vertex Pharmaceuticals from $275.00 to $280.00 and gave the stock a "buy" rating in a research note on Monday, June 13th. Cantor Fitzgerald assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, July 12th. They issued an "overweight" rating and a $365.00 target price for the company. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $291.00 to $307.00 and gave the stock an "overweight" rating in a research note on Friday, August 5th. HC Wainwright lifted their target price on shares of Vertex Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research note on Friday, August 5th. Finally, Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $250.00 to $253.00 and gave the company an "equal weight" rating in a report on Monday, August 8th. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $291.65.
几位分析师对该股发表了评论。6月13日，周一，Argus在一份研究报告中将Vertex PharmPharmticals的目标价从275.00美元上调至280.00美元，并给予该股“买入”评级。坎托·菲茨杰拉德在7月12日星期二的一份研究报告中对Vertex制药公司的股票进行了报道。他们对该公司的评级为“增持”，目标价为365.00美元。巴克莱将Vertex PharmPharmticals股票的目标价从291.00美元上调至307.00美元，并在周五的一份研究报告中给予该股“增持”评级。8月5日，在一份研究报告中，HC Wainwright将Vertex PharmPharmticals股票的目标价从275.00美元上调至300.00美元，并给予该股“买入”评级。最终，摩根士丹利在8日周一的一份报告中将顶点制药的目标价从250.00美元上调至253.00美元，并给予该公司“同等权重”的评级。6名分析师对该股的评级为持有，11名分析师发布了买入评级，一名分析师对该公司给予了强烈的买入评级。根据MarketBeat，该股目前的平均评级为“中等买入”，平均目标价为291.65美元.
Insiders Place Their Bets
Vertex Pharmaceuticals Stock Performance
NASDAQ:VRTX opened at $289.54 on Monday. The company has a current ratio of 4.50, a quick ratio of 4.36 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $74.26 billion, a price-to-earnings ratio of 23.41, a PEG ratio of 2.05 and a beta of 0.42. The firm's fifty day simple moving average is $287.25 and its 200 day simple moving average is $275.78. Vertex Pharmaceuticals Incorporated has a twelve month low of $176.36 and a twelve month high of $305.95.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.25 EPS for the quarter, topping analysts' consensus estimates of $3.05 by $0.20. Vertex Pharmaceuticals had a net margin of 38.26% and a return on equity of 31.22%. The firm had revenue of $2.20 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same quarter in the previous year, the business posted $2.80 EPS. The firm's revenue was up 22.5% compared to the same quarter last year. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 12.67 earnings per share for the current fiscal year.
顶点制药(纳斯达克：VRTX-GET评级)最近一次发布季度收益数据是在8月4日星期四。这家制药公司公布本季度每股收益为3.25美元，比分析师普遍预期的3.05美元高出0.20美元。Vertex PharmPharmticals的净利润率为38.26%，股本回报率为31.22%。该公司本季度营收为22.亿美元，而分析师预期为21.3亿美元。在去年同一季度，该业务公布的每股收益为2.80美元。与去年同期相比，该公司的收入增长了22.5%。作为一个整体，股票研究分析师预计，Vertex PharmPharmticals Inc.将公布本财年每股收益12.67美元。
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免费获取StockNews.com关于Vertex PharmPharmticals的研究报告(VRTX)
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.